Document is current
Any future updates will be listed below
-
Authors
Dorff, Tanya B. https://orcid.org/0000-0001-5990-298X
Blanchard, M. Suzette
Adkins, Lauren N.
Luebbert, Laura
Leggett, Neena
Shishido, Stephanie N.
Macias, Alan
Del Real, Marissa M.
Dhapola, Gaurav
Egelston, Colt
Murad, John P. https://orcid.org/0000-0003-0637-2414
Rosa, Reginaldo https://orcid.org/0000-0003-0984-8959
Paul, Jinny
Chaudhry, Ammar
Martirosyan, Hripsime
Gerdts, Ethan
Wagner, Jamie R.
Stiller, Tracey
Tilakawardane, Dileshni
Pal, Sumanta https://orcid.org/0000-0002-1712-0848
Martinez, Catalina
Reiter, Robert E.
Budde, Lihua E. https://orcid.org/0000-0003-1464-5494
D’Apuzzo, Massimo https://orcid.org/0000-0001-8146-0997
Kuhn, Peter
Pachter, Lior
Forman, Stephen J. https://orcid.org/0000-0002-2803-4152
Priceman, Saul J. https://orcid.org/0000-0002-8136-2112
- License Information
-
More Information
Article History
Received: 2 October 2023
Accepted: 5 April 2024
First Online: 12 June 2024
Competing interests
: T.B.D. is a consultant for AstraZeneca and Janssen. S.J.P. and S.J.F. are scientific advisors to and receive royalties from Mustang Bio. S.J.P. is also a scientific advisor and/or receives royalties from Imugene, Adicet Bio, Port Therapeutics and Celularity. S.J.P. and S.J.F. are listed as co-inventors on a patent on chimeric antigen receptors targeted to PSCA, which is owned by the City of Hope. The other authors declare no competing interests.
